




## Goat Anti-Feline IgG(H+L)

Cat. No.	Format	Size
6080-01	Purified (UNLB)	1.0 mg
6080-02	Fluorescein (FITC)	1.0 mg
6080-04	Alkaline Phosphatase (AP)	1.0 mL
6080-05	Horseradish Peroxidase (HRP)	1.0 mL



FLISA plate was coated with purified feline IgG. Immunoglobulin was detected with Goat Anti-Feline IgG(H+L)-FITC (SB Cat. No. 6080-02).

### Description

<b>Specificity</b>	Reacts with the heavy and light chains of feline IgG
<b>Source</b>	Pooled antisera from goats hyperimmunized with feline IgG
<b>Cross Adsorption</b>	None; may react with immunoglobulins from other species and the light chains of other feline immunoglobulins
<b>Purification</b>	Affinity chromatography on feline IgG covalently linked to agarose

### Applications

Quality tested applications include –

ELISA<sup>1-4</sup>  
FLISA

Other referenced applications include –

FC<sup>5,6</sup>  
IP<sup>7</sup>  
WB<sup>8</sup>

### Working Dilutions

<b>ELISA</b>	AP conjugate	1:2,000 – 1:4,000
	HRP conjugate	1:4,000 – 1:8,000
<b>FLISA</b>	FITC conjugate	1:200 – 1:400

**Other Applications** Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need.

**For Research Use Only. Not for Diagnostic or Therapeutic Use.**

## Handling and Storage

---

- The purified (UNLB) antibody is supplied as 1.0 mg purified immunoglobulin in 1.0 mL of borate buffered saline, pH 8.2. *No preservatives or amine-containing buffer salts added.* Store at 2-8°C.
- The fluorescein (FITC) conjugate is supplied as 1.0 mg in 1.0 mL of PBS/NaN<sub>3</sub>. Store at 2-8°C.
- The alkaline phosphatase (AP) conjugate is supplied as 1.0 mL in a stock solution of 50 mM Tris/1 mM MgCl<sub>2</sub>/50% glycerol, pH 8.0, containing NaN<sub>3</sub> as preservative. Store at 2-8°C or long-term at -20°C.
- The horseradish peroxidase (HRP) conjugate is supplied as 1.0 mL in a stock solution of 50% glycerol/50% PBS, pH 7.4. *No preservative added.* Store at 2-8°C or long-term at -20°C.
- Protect fluorochrome-conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.

## Warning

---

Some reagents contain sodium azide. Please refer to product specific SDS.

## References

---

1. Flynn JN, Cannon CA, Lawrence CE, Jarrett O. Polyclonal B-cell activation in cats infected with feline immunodeficiency virus. *Immunology*. 1994;81:626-30. (ELISA)
2. Lerner DL, Wagaman PC, Phillips TR, Prospero-Garcia O, Henriksen SJ, Fox HS, et al. Increased mutation frequency of feline immunodeficiency virus lacking functional deoxyuridine-triphosphatase. *Proc Natl Acad Sci USA*. 1995;92:7480-4. (ELISA)
3. Rigby MA, Hosie MJ, Willett BJ, Mackay N, McDonald M, Cannon C, et al. Comparative efficiency of feline immunodeficiency virus infection by DNA inoculation. *AIDS Res Hum Retroviruses*. 1997;13:405-12. (ELISA)
4. Armua-Fernandez MT, Castro OF, Crampet A, Bartzabal A, Hofmann-Lehmann R, Grimm F, et al. First case of peritoneal cystic echinococcosis in a domestic cat caused by *Echinococcus granulosus sensu stricto* (genotype 1) associated to feline immunodeficiency virus infection. *Parasitol Int*. 2014;63:300-2. (ELISA)
5. Barr MC, Huitron-Resendiz S, Selway DR, Henriksen SJ, Phillips TR. Exogenous glucocorticoids alter parameters of early feline immunodeficiency virus infection. *J Infect Dis*. 2000;181:576-86. (FC)
6. Barr MC, Billaud J, Selway DR, Huitron-Resendiz S, Osborn KG, Henriksen SJ, et al. Effects of multiple acute morphine exposures on feline immunodeficiency virus disease progression. *J Infect Dis*. 2000;182:725-32. (FC)
7. Nishii N, Takasu M, Kojima M, Hachisu T, Wakabayashi K, Iwasawa A, et al. Presence of anti-insulin natural autoantibodies in healthy cats and its interference with immunoassay for serum insulin concentrations. *Domest Anim Endocrinol*. 2010;38:138-45. (IP)
8. Lerner DL, Grant CK, de Parseval A, Elder JH. FIV infection of IL-2-dependent and -independent feline lymphocyte lines: host cells range distinctions and specific cytokine upregulation. *Vet Immunol Immunopathol*. 1998;65:277-97. (WB)